SCHEMBL23535737

SCHEMBL23535737

Cc1cc2cc(Br)ccc2nn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.46
BACE1 P56817 2/20 0.42
PSMB5 P28074 1/20 0.40
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 3/20 0.37
GAA P10253 1/20 0.37
CYP2A6 P11509 1/20 0.37
CYP1A2 P05177 3/20 0.37
CYP2C19 P33261 3/20 0.37
CYP2C9 P11712 2/20 0.37
CASP3 P42574 2/20 0.37
CYP2D6 P10635 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
MEN1 O00255 2/20 0.36
MAPT P10636 2/20 0.36
KMT2A Q03164 2/20 0.36
TDP2 O95551 1/20 0.36
NSD2 O96028 1/20 0.36
POLB P06746 1/20 0.36
BLM P54132 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8404442 0.78 CYP1A2 (0.54) BACE1PSMB5ALDH1A1KDM4ECYP2A6
SCHEMBL31271703 0.75 PIK3CG (0.46) ALDH1A1KDM4EGAACYP2A6MEN1
SCHEMBL26684871 0.75 PABPC1 (0.46) PABPC1BACE1PSMB5ALDH1A1KDM4E
SCHEMBL23648180 0.75 PABPC1 (0.46) PABPC1BACE1ALDH1A1KDM4ECYP2A6
SCHEMBL19004133 0.75 NPSR1 (0.36) ALDH1A1KDM4ECYP1A2MEN1MAPT
SCHEMBL30006808 0.75 PABPC1 (0.46) PABPC1BACE1ALDH1A1KDM4ECYP2A6
SCHEMBL18562311 0.75 PABPC1 (0.42) PABPC1BACE1PSMB5ALDH1A1KDM4E
SCHEMBL935575 0.72 CYP1A2 (0.63) BACE1PSMB5ALDH1A1KDM4EGAA
SCHEMBL29768297 0.72 BACE1 (0.58) PABPC1BACE1PSMB5ALDH1A1KDM4E
SCHEMBL4347785 0.72 BACE1 (0.58) PABPC1BACE1PSMB5ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727939-A1 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2026-04-22 EP disclosed
CN-115427035-B ENL/AF9 YEATS inhibitors 洛克菲勒大学 2025-04-22 CN disclosed
WO-2024259116-A1 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2024-12-19 WO disclosed
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY 2023-01-26 US disclosed
CN-115427035-A ENL/AF9YEATS inhibitors 洛克菲勒大学 2022-12-02 CN disclosed
EP-4076440-A1 INHIBITORS OF ENL/AF9 YEATS The Rockefeller University (US) 2022-10-26 EP disclosed
WO-2021127166-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS MLLT3, YEATS2, MLLT1 PABPC1 585/4885BACE1 4633/4885PSMB5 3014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.